Northland Securities analyst Carl Byrnes maintained a Hold rating on Esperion (NASDAQ:ESPR) on Tuesday, setting a price target of $42, which is approximately 3.51% below the present share price of $43.53.
Byrnes expects Esperion to post earnings per share (EPS) of -$2.84 for the second quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Esperion, with an average price target of $77.
The analysts price targets range from a high of $158 to a low of $42.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $1.84 million and a net profit of -$74.45 million. The company's market cap is $1.3 billion.
According to TipRanks.com, Northland Securities analyst Carl Byrnes is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.9% and a 36.22% success rate.
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.